ProQR Therapeutics NV
PRQR1.500USD
+0.040+2.74%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
161.57MValor de mercado
PerdaP/L TTM
Mais detalhes de ProQR Therapeutics NV Empresa
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Informações de ProQR Therapeutics NV
Código da empresaPRQR
Nome da EmpresaProQR Therapeutics NV
Data de listagemSep 18, 2014
CEOde Boer (Daniel Anton)
Número de funcionários166
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 18
EndereçoZernikedreef 9
CidadeLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 CK
Telefone31881667000
Sitehttps://www.proqr.com/
Código da empresaPRQR
Data de listagemSep 18, 2014
CEOde Boer (Daniel Anton)
Executivos da empresa ProQR Therapeutics NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
Outro
55.92%
Investidores
Investidores
Proporção
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
Outro
55.92%
Tipos de investidores
Investidores
Proporção
Hedge Fund
18.45%
Corporation
16.07%
Family Office
13.60%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
5.66%
Research Firm
3.13%
Individual Investor
2.03%
Outro
30.10%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
118
40.27M
38.22%
-4.52M
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.25M
5.94%
-348.47K
-5.28%
Sep 30, 2025
Privium Fund Management BV
5.00M
4.74%
+725.00
+0.01%
Sep 30, 2025
Affinity Asset Advisors LLC
3.60M
3.42%
+100.49K
+2.87%
Sep 30, 2025
abrdn Inc.
2.30M
2.18%
+448.48K
+24.24%
Sep 30, 2025
Morgan Stanley & Co. LLC
2.89M
2.75%
-171.79K
-5.61%
Sep 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
--
--
Sep 30, 2025
Kynam Capital Management LP
1.65M
1.57%
--
--
Sep 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
Proporção0.01%
Avantis International Small Cap Value ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
